Jenkins H et al. |
Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. |
2017 |
Clin Drug Investig |
pmid:27928738
|
Alba C et al. |
Antibiotic resistance in Helicobacter pylori. |
2017 |
Curr. Opin. Infect. Dis. |
pmid:28704226
|
Mishima E et al. |
Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. |
2017 |
Intern. Med. |
pmid:28674358
|
Shimoyama T et al. |
Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. |
2017 |
Intern. Med. |
pmid:28674348
|
Ustundag GH et al. |
The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. |
2017 |
Can J Gastroenterol Hepatol |
pmid:28656129
|
Peng X et al. |
Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. |
2017 |
Int J Med Sci |
pmid:28638276
|
Legendre T et al. |
[Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. |
2017 |
Encephale |
pmid:27178256
|
Choi HS et al. |
Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. |
2017 |
Jpn. J. Infect. Dis. |
pmid:27169951
|
Pastukh N et al. |
GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. |
2017 |
Helicobacter |
pmid:29058343
|
Tognetti L et al. |
Bullous impetigo during interstitial pneumonitis. |
2017 |
G Ital Dermatol Venereol |
pmid:29050448
|
Antonakos N et al. |
Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. |
2017 |
Crit Care |
pmid:28274246
|
Koratala A et al. |
Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. |
2017 |
Blood Purif. |
pmid:28268216
|
Fraser AG |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776748
|
Jung YS et al. |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776746
|
Makihara K et al. |
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:28711984
|
Fohner AE et al. |
PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. |
2017 |
Pharmacogenet. Genomics |
pmid:28146011
|
Sakurai K et al. |
Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. |
2017 |
World J. Gastroenterol. |
pmid:28216974
|
Awan S et al. |
Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. |
2017 |
Lung Cancer |
pmid:28213005
|
Su J et al. |
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. |
2017 |
Medicine (Baltimore) |
pmid:28207505
|
Branquinho D et al. |
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? |
2017 |
BMC Gastroenterol |
pmid:28202013
|